Q linea

Q linea Current Liabilities

The Current Liabilities of Q linea (QLINEA.ST) as of Nov 4, 2026 is 46.67 M SEK. In the previous year, Current Liabilities was 251.99 M SEK — a change of -81.48% (lower).

Current Liabilities

46.67 MSEK

YoY

-81.48%

Last updated:

Current Liabilities of Q linea is 2025 46.67 M SEK. Current Liabilities of Q linea was 2024 251.99 M SEK. It decreases by -81.48% lower compared to the previous year.

The Q linea Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
33.08 M SEK
Jan 1, 2019
28.70 M SEK
Jan 1, 2020
48.27 M SEK
Jan 1, 2021
50.33 M SEK
Jan 1, 2022
70.62 M SEK
Jan 1, 2023
46.76 M SEK
Jan 1, 2024
251.99 M SEK
Jan 1, 2025
46.67 M SEK
The Q linea Current Liabilities history
YEARCurrent LiabilitiesYoY
46.67 MSEK-81.48%
251.99 MSEK+438.91%
46.76 MSEK-33.79%
70.62 MSEK+40.32%
50.33 MSEK+4.27%
48.27 MSEK+68.18%
28.70 MSEK-13.25%
33.08 MSEK+74.93%
18.91 MSEK+135.87%
8.02 MSEK+59.28%
5.03 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q linea Stock analysis

What does Q linea do? Q-linea AB develops and manufactures in-vitro diagnostic solutions for infectious diseases, focusing on antibiotic susceptibility testing. The company's core product, ASTar, is a fully-automated instrument that provides susceptibility profiles within three to six hours directly from positive blood cultures. This enables early targeted antibiotic administration for sepsis identification in hospital patients, primarily serving hospital laboratories. The firm measures bacteria's antimicrobial susceptibility using its own disposables, which are integral to the ASTar system's operation. Q-linea AB's revenue model is based on selling the ASTar instrument and its associated disposables to hospital laboratories. The company's product is specifically designed for sepsis identification in hospital settings, where rapid and accurate antibiotic susceptibility testing is critical. By providing a faster solution than traditional methods, Q-linea targets hospital labs seeking to improve patient outcomes in sepsis cases. The company operates as a holding company with a focus on developing and manufacturing IVD solutions. Its primary customers are hospital laboratories, which purchase the ASTar system and disposables to streamline their diagnostic processes. The firm's business model centers on the sale of both the instrument and the consumable disposables, creating recurring revenue streams from ongoing disposables usage. Q linea is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Q linea stock

Current Liabilities of Q linea is 46.67 M SEK in 2025.

Current Liabilities of Q linea changed from 251.99 M SEK to 46.67 M SEK, representing a -81.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Q linea since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Q linea historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Q linea

All Key Metrics — Q linea